Azetidine Integrin Antagonists for Selective αvβ6 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing compounds targeting integrins, such as αvβ3 and αvβ5, do not effectively bind to αvβ6 integrins, leading to a need for novel compounds that can provide effective treatments for integrin-regulated diseases like cancer and fibrosis.
Innovation Solution
Development of azetidine derivatives with a rigid four-membered ring structure that specifically bind to the αvβ6 integrin receptor, utilizing various substituents and linkers to enhance binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used to target integrin receptors, then some level of binding is achieved, but binding affinity varies greatly between different receptors and compounds, leading to inconsistent treatment efficacy
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and structural features at particular positions within the compound molecule. The core structure contains specific substituents at defined locations that are optimized to interact with αvβ6 integrin, creating localized interaction points that enhance binding affinity and selectivity for this specific receptor subtype.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters of the compounds, including ring size, substituent types, and molecular configuration. These parameter adjustments are made to optimize the compounds' binding characteristics specifically for αvβ6 integrin, achieving enhanced affinity and selectivity through controlled modification of molecular properties.
2Reliability
If compounds are designed to bind one integrin receptor effectively, then high affinity is achieved for that receptor, but effectiveness at binding other receptors is compromised
Solution Approach 1:
The patent applies the inversion principle by reversing the conventional approach: instead of designing compounds to bind multiple integrin receptors broadly, the invention specifically targets αvβ6 integrin with high selectivity. This inverted strategy focuses on achieving superior binding to one specific receptor subtype rather than attempting multi-receptor coverage, thereby resolving the contradiction between affinity and versatility.
3Reliability
If novel compounds with specific structures are developed to improve αvβ6 binding, then treatment efficacy for αvβ6-related diseases is enhanced, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the compound into distinct functional modules: a core structural framework and specific substituent groups. This modular segmentation allows for systematic optimization of binding properties while maintaining a manageable structural complexity, as each segment can be independently designed and optimized for its specific function in receptor interaction.
Data Source
AI summary
The invention relates to novel compounds of formula (I), the compounds being capable of acting as avβ6 integrin antagonists, their use in the treatment of disease, their methods of manufacture and compositions comprising said compounds for such purposes (I) wherein R1 is selected from: R1a, —C(O)R1a, —C(O)OR1a —C(O)NHR1a, —C(O)N(R1a)2, —SO2R1a, wherein R1a are each independently selected from: alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl, each of which may be optionally substituted; R2 is selected from: hydrogen, halogen, optionally substituted alkyl or optionally substituted alkoxyl; R2a are each independently selected from: hydrogen, halogen, optionally substituted alkyl or optionally substituted alkoxyl; R3 is selected from: hydrogen, optionally substituted alkyl or optionally substituted alkoxyl; R4 is hydroxyl; Ar1 is an optionally substituted heteroaryl or bicyclic heteroaryl; and L is a linker; or a pharmaceutically acceptable salt thereof.